Lactate has become a big deal in both chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM). A by-product of anaerobic energy metabolism, lactate ordinarily gets pumped out of our cells in large amounts during exertion.
The lactate findings suggest that the energy needs of ME/CFS/FM patients are largely being addressed by glycolysis or anaerobic energy production.
Anaerobic energy production plays an important role in energy production, but when aerobic energy production is not available and it becomes the major source of energy it produces metabolites that produce the burning muscles, fatigue and other symptoms we associate with over-exercise. Continue reading
Surrogate end points in clinical research: hazardous to your health. – PubMed – NCBI – Obstet Gynecol. 2005 May
Surrogate end points in clinical research pose real danger.
A surrogate end point is an outcome measure, commonly a laboratory test, that substitutes for a clinical event of true importance.
Resistance to activated protein C, for example, has been used as a surrogate for venous thrombosis in women using oral contraceptives.
Other examples of inappropriate surrogate end points in contraception include the Continue reading
Guidelines for the Chronic Use of Opioid Analgesics from State Medical Boards – Opioid Guidelines As Adopted April 2017_FINAL.pdf
Adopted as policy by the Federation of State Medical Boards April 2017
In April 2015, the Federation of State Medical Boards (FSMB) Chair, J. Daniel Gifford, MD, FACP, appointed the Workgroup on FSMB’s Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain to review the current science for treating chronic pain with opioid analgesics and to revise the Model Policy as appropriate.
In updating its existing policy, the FSMB sought input from a diverse group of medical and policy stakeholders that ranged from experts in pain medicine and addiction to government officials and other thought leaders.
This what the CDC should have done as well, but did not. Continue reading
On Thursday, June 8, the U.S. Food and Drug Administration “requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market,” the FDA said in a statement.
Apparently Opana ER, an extended release form of the opioid drug oxymorphone, was being crushed up and injected by people seeking to abuse it.
“After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.” Continue reading
This is an example of how new drugs developed with the latest new technologies can lead to dangerous unintended side-effects that only become apparent later after many subjects have been “treated”.
When a new technology, like CRISPR gene editing, is used we cannot use past experience to assume anything and cannot predict results precisely because we’re doing something categorically different from before.
As CRISPR-Cas9 starts to move into clinical trials, a new study published in Nature Methods has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome. Continue reading
Improving the analgesic effectiveness of opioids while also reducing the adverse effects is a major goal of pain research.
One approach to this problem has been to combine drugs such as cannabinoids with opioids to determine if this might reduce the dose of opioid required to produce analgesia.
In this experiment, male nonhuman primates (rhesus macaques) were administered a range of doses of THC in combination with cumulative doses of heroin to determine if the combinations produced greater analgesia than that observed with heroin alone.
Briefly, the animals were secured in standard primate ch airs, tails were shaved, and dipped in a mixed order in three different water temperatures (40 °, 50 °, and 55 °C) until the animal rapidly withdrew his tail, or 20 seconds elapsed. Continue reading
It has long been assumed that chronic nerve pain is caused by hypersensitivity in the neurons that transmit pain.
Researchers at Karolinska Institutet in Sweden now show that another kind of neuron that normally allows us to feel pleasant touch sensation, can switch function and instead signal pain after nerve damage.
The results, which are presented in the journal Science, can eventually lead to more effective pain treatments. Continue reading
Ketamine for Pain Management, Treatment of Depression – Linda Peckel – May 30, 2017
Ketamine may alleviate depression, pain, and side effects associated with opioid treatment, and may thus represent an attractive adjunct therapy for pain management, according to a novel population analysis recently published in Scientific Reports.
Nearly half of all patients with depression taking conventional antidepressants discontinue their treatment prematurely.
Researchers have sought alternatives to standard antidepressants, for which therapeutic effects are delayed by 2 to 10 weeks. Continue reading
A new study from King’s College London offers clues as to why chronic pain can persist, even when the injury that caused it has gone.
Although still in its infancy, this research could explain how small and seemingly innocuous injuries leave molecular ‘footprints’ which add up to more lasting damage, and ultimately chronic pain.
While chronic pain can have many different causes, the outcome is often the same: an overly sensitive nervous system which responds much more than it normally would. Continue reading
» call MORGAN & MORGAN ..tell your story… refer to chronic pain patient class action PHARMACIST STEVE June 19, 2017 by Steve Ariens
Chronic Pain Patients – Call Now
Morgan & Morgan Lawyers
Ask for the medical malpractice department.
Refer to chronic pain patient class action and tell your story. Continue reading